ATE250924T1 - Cyklosporin, hyaluronsäure und polysorbate enthaltenes augenarzneimittel - Google Patents

Cyklosporin, hyaluronsäure und polysorbate enthaltenes augenarzneimittel

Info

Publication number: ATE250924T1
Authority: AT; Austria
Prior art keywords: polysorbates; hyaluronic acid; containing cyclosporine; eye medicinal; medicinal containing
Prior art date: 2000-04-07

Application number

AT01107223T

Other languages

English (en)

Inventor

Napoli Guido Di

Original Assignee

Medidom Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-07

Filing date

2001-03-23

Publication date

2003-10-15

2001-03-23 Application filed by Medidom Lab filed Critical Medidom Lab

2003-10-15 Application granted granted Critical

2003-10-15 Publication of ATE250924T1 publication Critical patent/ATE250924T1/de

Links

KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title 1
108010036949 Cyclosporine Proteins 0.000 title 1
229960001265 ciclosporin Drugs 0.000 title 1
229930182912 cyclosporin Natural products 0.000 title 1
229920002674 hyaluronan Polymers 0.000 title 1
229960003160 hyaluronic acid Drugs 0.000 title 1
229920000136 polysorbate Polymers 0.000 title 1
229940068965 polysorbates Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT01107223T 2000-04-07 2001-03-23 Cyklosporin, hyaluronsäure und polysorbate enthaltenes augenarzneimittel ATE250924T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH6942000		2000-04-07

Publications (1)

Publication Number	Publication Date
ATE250924T1 true ATE250924T1 (de)	2003-10-15

Family

ID=4529494

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01107223T ATE250924T1 (de)	2000-04-07	2001-03-23	Cyklosporin, hyaluronsäure und polysorbate enthaltenes augenarzneimittel

Country Status (19)

Country	Link
US (2)	US6677304B2 (de)
EP (1)	EP1142566B1 (de)
JP (1)	JP2001316284A (de)
CN (1)	CN1185009C (de)
AR (1)	AR028291A1 (de)
AT (1)	ATE250924T1 (de)
AU (1)	AU778858B2 (de)
BR (1)	BR0101332A (de)
CA (1)	CA2342133C (de)
CZ (1)	CZ294385B6 (de)
DE (1)	DE60100866T2 (de)
DK (1)	DK1142566T3 (de)
ES (1)	ES2206363T3 (de)
IL (1)	IL142268A (de)
PL (1)	PL201055B1 (de)
PT (1)	PT1142566E (de)
SK (1)	SK285220B6 (de)
TR (1)	TR200302105T4 (de)
ZA (1)	ZA200102769B (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2445763A1 (en) *	2001-05-01	2002-11-07	Angiotech Pharmaceuticals Inc.	Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
US20030157161A1 (en) *	2001-05-01	2003-08-21	Angiotech Pharmaceuticals, Inc.	Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
US7354574B2 (en)	2002-11-07	2008-04-08	Advanced Ocular Systems Limited	Treatment of ocular disease
FR2848106B1 (fr) *	2002-12-06	2006-11-17	Oreal	Composition de teinture pour fibres keratiniques comprenant un alcool gras non oxyalkylene, un colorant d'oxydation, un polymere associatif et un amide d'une alcanolamine et d'un acide gras en c14-c30.
US7326256B2 (en)	2002-12-06	2008-02-05	L'ORéAL S.A.	Composition for the oxidation dyeing of keratin fibers, comprising at least one non-oxyalkenylated fatty alcohol, at least one oxidation dye, at least one associative polymer, and at least one amide of an alkanolamine and a C14-C30 fatty acid
JP2004262777A (ja) *	2003-02-27	2004-09-24	Shiseido Co Ltd	アセチル化ヒアルロン酸含有眼用医薬組成物
US20050196370A1 (en) *	2003-03-18	2005-09-08	Zhi-Jian Yu	Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
AU2003228126A1 (en) *	2003-05-02	2004-11-23	Arturo Jimenez Bayardo	Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution
US7947295B2 (en) *	2003-06-13	2011-05-24	Alcon, Inc.	Ophthalmic compositions containing a synergistic combination of two polymers
US7083802B2 (en)	2003-07-31	2006-08-01	Advanced Ocular Systems Limited	Treatment of ocular disease
AU2004274026A1 (en)	2003-09-18	2005-03-31	Macusight, Inc.	Transscleral delivery
US7083803B2 (en)	2003-09-19	2006-08-01	Advanced Ocular Systems Limited	Ocular solutions
US7087237B2 (en)	2003-09-19	2006-08-08	Advanced Ocular Systems Limited	Ocular solutions
CA2553381C (en) *	2004-01-20	2011-03-22	Allergan, Inc.	Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7135455B2 (en) *	2004-11-15	2006-11-14	Allergan, Inc	Methods for the therapeutic use of cyclosporine components
WO2006067608A1 (en) *	2004-12-22	2006-06-29	Laboratoire Medidom S.A.	Aqueous formulations based on sodium hyaluronate for parenteral use
CA2597590A1 (en)	2005-02-09	2006-08-17	Macusight, Inc.	Formulations for ocular treatment
US8663639B2 (en)	2005-02-09	2014-03-04	Santen Pharmaceutical Co., Ltd.	Formulations for treating ocular diseases and conditions
CN100478025C (zh) *	2005-03-25	2009-04-15	中国科学院上海药物研究所	一种环孢菌素a眼用微乳制剂及其制备方法
CN101242825B (zh) *	2005-07-01	2011-03-30	希格马托制药工业公司	L-肉碱和/或烷酰基l-肉碱用于制备滴眼剂形式的眼用生理学补充剂或药物的用途
US20070014760A1 (en) *	2005-07-18	2007-01-18	Peyman Gholam A	Enhanced recovery following ocular surgery
CA2615990A1 (en)	2005-07-18	2007-01-25	Minu, L.L.C.	Enhanced ocular neuroprotection/neurostimulation
US7501393B2 (en) *	2005-07-27	2009-03-10	Allergan, Inc.	Pharmaceutical compositions comprising cyclosporins
US20080306022A1 (en) *	2005-10-12	2008-12-11	Kenji Miyamoto	Agent for Applying to Mucosa and Method for the Production Thereof
US9839667B2 (en)	2005-10-14	2017-12-12	Allergan, Inc.	Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) *	2005-10-14	2010-06-29	Gregg Feinerman	Prevention and treatment of ocular side effects with a cyclosporin
AU2006311577B2 (en)	2005-11-09	2013-02-07	Zalicus Inc.	Methods, compositions, and kits for the treatment of medical conditions
TWI630207B (zh)	2005-12-13	2018-07-21	英塞特控股公司	作為傑納斯激酶（ＪＡＮＵＳＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
WO2007092620A2 (en)	2006-02-09	2007-08-16	Macusight, Inc.	Stable formulations, and methods of their preparation and use
US7655625B2 (en)	2006-02-13	2010-02-02	Allergan, Inc.	Methods of treating blepharospasm using cyclosporine components
US20070212420A1 (en) *	2006-03-10	2007-09-13	Bausch & Lomb Incorporated	Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
US8222271B2 (en)	2006-03-23	2012-07-17	Santen Pharmaceutical Co., Ltd.	Formulations and methods for vascular permeability-related diseases or conditions
WO2008002582A2 (en) *	2006-06-27	2008-01-03	Riolan Technologies, Inc.	Ultraviolet absorbing ophthalmic compositions
AU2016203191B2 (en) *	2006-07-25	2018-03-01	Allergan, Inc.	Cyclosporin compositions
US9561178B2 (en) *	2006-07-25	2017-02-07	Allergan, Inc.	Cyclosporin compositions
WO2008035246A2 (en)	2006-07-28	2008-03-27	Novagali Pharma Sa	Compositions containing quaternary ammonium compounds
CN101896160A (zh) *	2006-10-17	2010-11-24	阿勒根公司	环胞菌素组合物
JP2010522774A (ja) *	2007-03-30	2010-07-08	フォベア、ファルマスティカル、ソシエテ、アノニム	血管新生眼疾患を治療するための方法
EP3070090B1 (de)	2007-06-13	2018-12-12	Incyte Holdings Corporation	Verwendung der salze des janus-kinasehemmers (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropannitril
EA019867B1 (ru) *	2007-10-08	2014-06-30	Фовея Фармасьютикалс	Водные офтальмологические препараты
AU2008310956B2 (en)	2007-10-08	2014-08-07	Aurinia Pharmaceuticals Inc.	Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US20100016219A1 (en) *	2008-07-19	2010-01-21	Jerry Zhang	Ophthalmic compositions containing solubilized cyclosporin
CL2009001884A1 (es) *	2008-10-02	2010-05-14	Incyte Holdings Corp	Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
GB0904423D0 (en) *	2009-03-14	2009-04-29	Univ Strathclyde	Improving the solubility of chemicals
EP3643312A1 (de)	2009-05-22	2020-04-29	Incyte Holdings Corporation	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- oder heptannitril als jak-inhibitoren
AR076794A1 (es)	2009-05-22	2011-07-06	Incyte Corp	Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
MX338355B (es) *	2009-06-09	2016-04-13	Aurinia Pharmaceuticals Inc	Sistemas de suministro de farmaco topico para uso oftalmico.
AR078012A1 (es)	2009-09-01	2011-10-05	Incyte Corp	Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
EP3050882B1 (de)	2010-03-10	2018-01-31	Incyte Holdings Corporation	Piperidin-4-yl-azetidin-derivate als jak1-inhibitoren
SG10201503983QA (en)	2010-05-21	2015-06-29	Incyte Corp	Topical Formulation for a JAK Inhibitor
CN103415515B (zh)	2010-11-19	2015-08-26	因塞特公司	作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
US9034884B2 (en)	2010-11-19	2015-05-19	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
PE20140832A1 (es)	2011-06-20	2014-07-14	Incyte Corp	Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
RU2639393C2 (ru) *	2011-11-15	2017-12-21	Аллерган, Инк.	Состав пролонгированного действия циклоспорина формы 2
AU2012339701B8 (en) *	2011-11-15	2017-11-16	Allergan, Inc.	Autoclavable suspensions of cyclosporin A Form 2
FR2988297B1 (fr)	2012-03-22	2014-03-28	Thea Lab	Solution ophtalmique aqueuse a base de ciclosporine a sans conservateur
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PL2919766T3 (pl)	2012-11-15	2021-10-04	Incyte Holdings Corporation	Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
CN105189509B (zh)	2013-03-06	2017-12-19	因赛特公司	用于制备jak抑制剂的方法及中间体
EP4137139A1 (de)	2013-07-10	2023-02-22	Matrix Biology Institute	Hyaluronanzusammensetzungen mit hoher elastizität und verwendungen davon
SG10201912203XA (en)	2013-08-07	2020-02-27	Incyte Corp	Sustained release dosage forms for a jak1 inhibitor
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
KR20170030093A (ko) *	2014-07-18	2017-03-16	알레간 인코포레이티드	결막하 및 눈주위 주사를 위한 사이클로스포린 a의 현탁액 조성물
WO2017053339A1 (en)	2015-09-24	2017-03-30	Matrix Biology Institute	High elasticity hyaluronan compositions and methods of use thereof
KR101635915B1 (ko) *	2016-02-15	2016-07-04	삼천당제약주식회사	사이클로스포린과 히알루론산 또는 이의 염을 포함하는 수용액 형태의 안과용 조성물
EP3525799B1 (de) *	2016-10-14	2022-01-26	i.com Medical GmbH	Verfahren zur herstellung, wiederherstellung und erhaltung von homöostase der augenoberfläche
US20190224275A1 (en)	2017-05-12	2019-07-25	Aurinia Pharmaceuticals Inc.	Protocol for treatment of lupus nephritis
WO2019060696A1 (en) *	2017-09-25	2019-03-28	Surface Pharmaceuticals, Inc.	OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE
WO2019113487A1 (en)	2017-12-08	2019-06-13	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3746429B1 (de)	2018-01-30	2022-03-09	Incyte Corporation	Verfahren zur herstellung von (1-(3-fluor-2-trifluormethyl)isonicotinyl)piperidin-4-on)
WO2019191700A1 (en) *	2018-03-29	2019-10-03	Mati Therapeutics	Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment
PT3773593T (pt)	2018-03-30	2024-06-25	Incyte Corp	Tratamento da hidradenite supurativa com inibidores de jak
JP2022516099A (ja) *	2018-12-27	2022-02-24	サーフィスオフサルミクス，インコーポレイテッド	眼科用医薬組成物及び癌表面疾患の処置方法
WO2021008668A1 (en)	2019-07-12	2021-01-21	Pharmathen S.A.	Preservative free pharmaceutical composition for ophthalmic administration containing cyclosporine
JP7717065B2 (ja)	2019-11-22	2025-08-01	インサイトコーポレーション	Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
WO2021120937A1 (zh) *	2019-12-17	2021-06-24	童妍(上海)医疗器械有限公司	转甲状腺素蛋白进入眼内以及在制备滴剂中的应用
US20210290527A1 (en) *	2020-03-23	2021-09-23	Eyegate Pharmaceuticals, Inc.	Compositions and Methods for Treatment of Ocular Conditions
GR1010012B (el)	2020-05-12	2021-05-27	Φαρματεν Α.Β.Ε.Ε.	Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον κυκλοσπορινη
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
US11510930B2 (en) *	2020-08-26	2022-11-29	Somerset Therapeutics, Llc	Gatifloxacin, prednisolone, and bromfenac compositions and methods
US12102632B2 (en)	2020-08-26	2024-10-01	Somerset Therapeutics, Llc	Quinolone dispersions
CN117979951A (zh)	2021-05-10	2024-05-03	瑟菲斯眼科股份有限公司	一种用于缓解眼部疼痛的硫酸软骨素的用途
US12440510B2 (en)	2021-05-10	2025-10-14	Surface Ophthalmics, Inc.	Use of chondroitin sulfate for relieving ocular pain
US20250360217A1 (en) *	2022-07-20	2025-11-27	Asahi Kasei Kabushiki Kaisha	Hyaluronic acid derivative pharmaceutical composition and method of producing pharmaceutical composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US592048A (en) *		1897-10-19		Drill-press
WO1989001772A1 (en) *	1987-09-03	1989-03-09	University Of Georgia Research Foundation, Inc.	Ocular cyclosporin composition
CA1340994C (en) *	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Treatment of conditions and disease
JPH0558906A (ja) *	1991-09-06	1993-03-09	Sankyo Co Ltd	シクロスポリン点眼製剤
SG45449A1 (en) *	1992-05-13	1998-01-16	Sandoz Ltd	Ophthalmic compositions
US5474979A (en) *	1994-05-17	1995-12-12	Allergan, Inc.	Nonirritating emulsions for sensitive tissue
JP2936209B2 (ja) *	1994-06-01	1999-08-23	ユーハンコーポレーション	サイクロスポリン含有組成物およびその製造方法
JPH1160505A (ja) *	1997-05-20	1999-03-02	Senju Pharmaceut Co Ltd	防腐組成物

2001
- 2001-03-23 AT AT01107223T patent/ATE250924T1/de active
- 2001-03-23 DK DK01107223T patent/DK1142566T3/da active
- 2001-03-23 DE DE60100866T patent/DE60100866T2/de not_active Expired - Lifetime
- 2001-03-23 EP EP01107223A patent/EP1142566B1/de not_active Expired - Lifetime
- 2001-03-23 PT PT01107223T patent/PT1142566E/pt unknown
- 2001-03-23 ES ES01107223T patent/ES2206363T3/es not_active Expired - Lifetime
- 2001-03-23 TR TR2003/02105T patent/TR200302105T4/xx unknown
- 2001-03-26 AR ARP010101408A patent/AR028291A1/es not_active Application Discontinuation
- 2001-03-27 US US09/818,213 patent/US6677304B2/en not_active Expired - Fee Related
- 2001-03-27 IL IL142268A patent/IL142268A/en not_active IP Right Cessation
- 2001-03-27 CA CA2342133A patent/CA2342133C/en not_active Expired - Fee Related
- 2001-04-04 CZ CZ20011229A patent/CZ294385B6/cs not_active IP Right Cessation
- 2001-04-04 AU AU33404/01A patent/AU778858B2/en not_active Ceased
- 2001-04-04 ZA ZA200102769A patent/ZA200102769B/xx unknown
- 2001-04-05 SK SK460-2001A patent/SK285220B6/sk not_active IP Right Cessation
- 2001-04-06 PL PL346926A patent/PL201055B1/pl unknown
- 2001-04-06 BR BR0101332-7A patent/BR0101332A/pt active Search and Examination
- 2001-04-06 CN CNB011124849A patent/CN1185009C/zh not_active Expired - Fee Related
- 2001-04-06 JP JP2001109077A patent/JP2001316284A/ja active Pending
2003
- 2003-11-21 US US10/721,007 patent/US6953776B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1142566A1 (de)	2001-10-10
US6953776B2 (en)	2005-10-11
ZA200102769B (en)	2001-10-05
EP1142566B1 (de)	2003-10-01
DE60100866T2 (de)	2004-07-29
CN1317342A (zh)	2001-10-17
PL346926A1 (en)	2001-10-08
US20010041671A1 (en)	2001-11-15
SK285220B6 (sk)	2006-09-07
DK1142566T3 (da)	2004-02-09
AR028291A1 (es)	2003-04-30
PT1142566E (pt)	2004-02-27
DE60100866D1 (de)	2003-11-06
SK4602001A3 (en)	2001-11-06
IL142268A (en)	2007-08-19
IL142268A0 (en)	2002-03-10
CA2342133A1 (en)	2001-10-07
AU778858B2 (en)	2004-12-23
US6677304B2 (en)	2004-01-13
TR200302105T4 (tr)	2004-02-23
JP2001316284A (ja)	2001-11-13
CZ20011229A3 (cs)	2001-11-14
CN1185009C (zh)	2005-01-19
CZ294385B6 (cs)	2004-12-15
US20040106546A1 (en)	2004-06-03
PL201055B1 (pl)	2009-03-31
BR0101332A (pt)	2001-11-06
AU3340401A (en)	2001-10-11
ES2206363T3 (es)	2004-05-16
CA2342133C (en)	2011-02-01

Legal Events

Date

Code

Title

Description

2004-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1142566

Country of ref document: EP

Publication	Publication Date	Title
ATE250924T1 (de)	2003-10-15	Cyklosporin, hyaluronsäure und polysorbate enthaltenes augenarzneimittel
NL1015859A1 (nl)	2001-07-27	Farmaceutische preparaten.
ZA200407868B (en)	2005-04-26	17alpha-Alkyl-17beta-oxy-estratrienes, uses thereof and pharmaceutical preparations.
ZA200105407B (en)	2003-01-02	Taste-Masked Pharmaceutical Particles.
DE60126321D1 (de)	2007-03-15	Gelsystem zur ocularen verabreichung von arzneimitteln
MA26008A1 (fr)	2003-12-31	Bouteille et bouchage.
EE05109B1 (et)	2008-12-15	Sulfoonamiidi derivaadid, nende kasutamine meditsiinis ning meetod nende valmistamiseks
ITTO20010005A0 (it)	2001-01-09	Formulazione farmaceutica.
NO20022970D0 (no)	2002-06-20	Hydrogel-drevet medikamentdoseringsform
HUP0204514A3 (en)	2004-07-28	Pyridinylimidazoles, pharmaceutical compositions containing them and their use
NO20030627L (no)	2003-04-08	Hydrogel-drevet medikament doseringsform
ITFI20000154A0 (it)	2000-07-07	Convogliatore radioelettrico asimmetrico terapeutico.
EP1196156A4 (de)	2005-01-12	Transnasale anticonvulsive zusammensetzungen und ein abgestimmtes verfahren
NO20040702L (no)	2004-05-19	Kombinerte preparater som inneholder 1,4-benzotiepin-1,1-dioksidderivater og andre aktive substanser og anvendelsen derav
ZA200208761B (en)	2002-11-29	Pharmaceutical form of administration for peptides, methods for its production and use.
EP1299337A4 (de)	2004-10-13	Hydroxyphenstatin und seine promedikamente
FR2850377B1 (fr)	2009-02-20	Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2809731B1 (fr)	2002-07-19	Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique
NO20031246L (no)	2003-03-18	Farmasöytisk blanding
GB0127706D0 (en)	2002-01-09	The Drug and bug cap
IL154240A0 (en)	2003-07-31	4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
MXPA03001826A (es)	2003-06-04	Derivados de arilpiperazina.
HUP0300222A3 (en)	2004-08-30	Novel lhrh-antagonists, production and use thereof as medicament
HUP0201696A3 (en)	2002-10-28	Cyclic peptides, pharmaceutical compositions comprising thereof and their use
DE60003662D1 (de)	2003-08-07	Pyridothienodiazepine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen